To this hypothesis, we measured Tau acetylation in protein extracts from neuroblastoma cells treated with the selective Hdac6 inhibitor Tubastatin A (TubA), combined or not with the proteasomal inhibitor MG-132 treatment. This evidence concerns the gene MAPT and neuroblastoma.